24603-63-2

Usage

Uses

Used in Scientific Research:
5-Chloro-1,2-benzisoxazol-3(2H)-one is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure and reactivity make it a valuable building block in the synthesis of complex molecules, which can be further utilized in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Chloro-1,2-benzisoxazol-3(2H)-one is used as a key component in the synthesis of potential drug candidates. Its presence in the molecular structure can impart specific biological activities, such as antimicrobial, anti-inflammatory, or analgesic properties, which can be harnessed for the development of new therapeutic agents.
Used in Agrochemical Industry:
5-Chloro-1,2-benzisoxazol-3(2H)-one is also employed in the agrochemical industry as a starting material for the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their efficacy in controlling pests and weeds, thereby improving crop yields and protecting agricultural resources.
Used in Specialty Chemicals:
In the specialty chemicals sector, 5-Chloro-1,2-benzisoxazol-3(2H)-one is used as a raw material for the production of various chemical intermediates and fine chemicals. Its versatility in chemical reactions allows for the creation of a wide range of products with diverse applications, such as dyes, pigments, and polymers.

Upstream product

• 21725-69-9 3-hydroxybenzisoxazole 
• 4068-78-4 methyl 5-chloro-2-hydroxybenzoate 
• 37551-43-2 N-(5-chlorosalicyl) hydroxamic acid 
• 37551-43-2 5-chloro-2,N-dihydroxy-benzamide 
• 16263-53-9 3,5-dichloro-1,2-benzoisoxazole 

Downstream Products

• 24603-54-1 3-benzoyloxy-5-chloro-benzo[d]isoxazole 
• 24603-55-2 4-methoxy-benzoic acid 5-chloro-benzo[d]isoxazol-3-yl ester 
• 16263-53-9 3,5-dichloro-1,2-benzoisoxazole 
• 16263-61-9 5-chloro-3-phenoxy-benzo[d]isoxazole 
• 24603-52-9 5-chloro-2-cyclohexanecarbonyl-benzo[d]isoxazol-3-one 
• 24603-60-9 5-chloro-3-(toluene-4-sulfonyloxy)-benzo[d]isoxazole 
• 24603-59-6 5-chloro-2-(4-nitro-benzoyl)-benzo[d]isoxazol-3-one 

Relevant academic research and scientific papers

Benzo[d]isoxazol-3-ol DAAO inhibitors

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein Z1 is N or CR3; Z2 is N or CR4; Z3is O or S; A is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof; R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR5 and SO2NH2; R5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl; at least one of R1, R2, R3 and R4 is other than hydrogen; and at least one of Z1 and Z2 is other than N.

BENZISOXAZOLES

The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein m represents an integer from 1 to 3; X represents amino, hydroxy, -oxo or -Z-R1; Y is absent when X represents -Z-R1 and -(C=O)-R66 when X represents oxo; Z represents carbonyl, -oxy-carbonyl- or -NR 55-carbonyl-; R1 represents C1-4alkyl, Ar1, Ar1-C1-4a1ky1-, -NR3R4 or -Het1; R2 represents hydrogen, halo, nitro, hydroxycarbonyl-, C1-4alkyloxy or C1-4alkyl; R33 and R4 are each independently selected from hydrogen, Ar33 or C1-4alkyl; R5 represents hydrogen, C1-4alkylcarbonyl- or Ar4-carbonyl-; R6 represents a substituent selected from the group consisting of C1.4alkyl, Ar55, Ar6-C1-4alkyl- or NR7R8; R7 and R8 are each independently selected from hydrogen, Het4 or C1-4alkyl; Het1 represents a heterocycle selected from oxazolyl, isoxazolyl, imidazolyl or pyrazolyl wherein said heterocycle is optionally substituted with one, two or three substituents selected from the group consisting of amino, C1-4alkyl, hydroxy-C1-4alkyl, phenyl, phenyl-C1-4alkyl- and phenyl substituted with one or more halo substituents; Het4 represents a heterocycle selected from oxazolyl or isoxazolyl, wherein said heterocycle is optionally substituted with one or more substituents selected from the group consisting of amino, C1-4alkyl, hydroxy-C1-4alkyl-, phenyl, phenyl-Cl-4alkyl and phenyl substituted with one or more halo substituents; and Ar1, Ar2, Ar3, Ar4, Ar5 or Ar6 each independently represents phenyl optionally substituted one or where possible two or more substituents selected from halo, nitro, C1-4alkyl, hydroxy or C1-4alkyloxy-.

Isoxazole derivatives

An isoxazole compound having the following formula: wherein R1 represents hydrogen, halogen, alkyl, alkoxy, hydroxyl, alkylthio, amino, alkanoyl, alkanoylamino, alkanoyloxy, alkoxycarbonyl, carboxy, (alkylthio)thiocarbonyl, carbamoyl, nitro or cyano; R2 represents an amino; m is 1; n is 1 to 6; ring A represents a phenyl ring or a naphthyl ring; and X represents oxygen or sulfur. The isoxazole compound has an excellent monoamine oxidase inhibitory activity, and is useful for treating Parkinson's disease, depression and Alzheimer's disease.

Synthesis and Biological Evaluation of 1-(1,2-Benzisothiazol-3-yl)- and (1,2-Benzisoxazol-3-yl)piperazine Derivatives as Potential Antipsychotic Agents

Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens.Structure-activity relationships within the series are discussed.Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests.It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h.The compound's lack of typical neuroleptic-like effects in therat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy.Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile.Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.